INTRODUCTION: Cancer patients experience multiple concurrent symptoms. This exploratory analysis assessed symptom burden among patients undergoing chemotherapy for breast cancer to identify distinct subgroups of patients who experience differential symptom burden and assessed whether the patient subgroups were associated with deleterious quality of life (QOL) outcomes. MATERIALS AND METHODS: Women (N = 133) with stage I and II breast cancer undergoing adjuvant chemotherapy after primary surgery were evaluated at baseline and at the end of chemotherapy using the Memorial Symptom Assessment Scale (MSAS) and the SF-36 QOL questionnaire. Post treatment MSAS symptoms were included in hierarchical cluster analysis. Two patient subgroups were identified that corresponded to a high-symptom prevalence group and a low-symptom group. RESULTS AND DISCUSSION: No marked, statistically significant differences were found between groups on demographic, symptoms, QOL, or treatment variables at baseline. Patients in the high-symptom cluster were more likely to have stage I disease (p < 0.05). The two groups of patients showed significant differences in end-of-treatment symptoms and QOL scores (p < 0.05). The high-symptom burden group was more likely to report greater symptom prevalence and poorer QOL. CONCLUSIONS: Future research needs to examine why these differences occur despite similarities in treatment and how symptom burden can be reduced for the high-symptom prevalence group.
INTRODUCTION:Cancerpatients experience multiple concurrent symptoms. This exploratory analysis assessed symptom burden among patients undergoing chemotherapy for breast cancer to identify distinct subgroups of patients who experience differential symptom burden and assessed whether the patient subgroups were associated with deleterious quality of life (QOL) outcomes. MATERIALS AND METHODS:Women (N = 133) with stage I and II breast cancer undergoing adjuvant chemotherapy after primary surgery were evaluated at baseline and at the end of chemotherapy using the Memorial Symptom Assessment Scale (MSAS) and the SF-36 QOL questionnaire. Post treatment MSAS symptoms were included in hierarchical cluster analysis. Two patient subgroups were identified that corresponded to a high-symptom prevalence group and a low-symptom group. RESULTS AND DISCUSSION: No marked, statistically significant differences were found between groups on demographic, symptoms, QOL, or treatment variables at baseline. Patients in the high-symptom cluster were more likely to have stage I disease (p < 0.05). The two groups of patients showed significant differences in end-of-treatment symptoms and QOL scores (p < 0.05). The high-symptom burden group was more likely to report greater symptom prevalence and poorer QOL. CONCLUSIONS: Future research needs to examine why these differences occur despite similarities in treatment and how symptom burden can be reduced for the high-symptom prevalence group.
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; N Coyle; T Smart-Curley; N Kemeny; L Norton; W Hoskins Journal: Qual Life Res Date: 1994-06 Impact factor: 4.147
Authors: Kristine A Donovan; Brent J Small; Michael A Andrykowski; Pamela Munster; Paul B Jacobsen Journal: Health Psychol Date: 2007-07 Impact factor: 4.267
Authors: Nikoloas Papachristou; Payam Barnaghi; Bruce A Cooper; Xiao Hu; Roma Maguire; Kathi Apostolidis; Jo Armes; Yvette P Conley; Marilyn Hammer; Stylianos Katsaragakis; Kord M Kober; Jon D Levine; Lisa McCann; Elisabeth Patiraki; Steven M Paul; Emma Ream; Fay Wright; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-08-30 Impact factor: 3.612